# Rituximab in Metastatic Melanoma

> **NCT01032122** · PHASE1 · TERMINATED · sponsor: **Medical University of Vienna** · enrollment: 9 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** rituximab

## Key facts

- **NCT ID:** NCT01032122
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-10
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** the only reason is that recruitment was not sufficient to meet the planned patient numbers, because complete remissions are still infrequent.
- **Last updated:** 2013-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01032122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01032122, "Rituximab in Metastatic Melanoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01032122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*